Compare Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 (SLVO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 vs Vertex Pharmaceuticals Incorporated — how do they compare? Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 trades at $69.3, while Vertex Pharmaceuticals Incorporated trades at $528.02 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 nearer its low. Which is the better fit depends on your goals.
| SLVO | VRTX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $107.41 | $529.65 |
52-Week Low | $61.81 | $376.62 |
Market Cap | — | $132.79B |
Enterprise Value | — | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLVO is currently trading at $67.78, up 2.63% with a bullish technical signal supported by moving averages. The stock recently crossed below its 50-day moving average of $73.20, indicating potential volatility. Technical indicators show mixed signals with RSI suggesting overbought conditions while ADX indicates strong trend momentum.
The outlook remains cautiously optimistic given the bullish technical setup, though fundamental data is limited. Key risks include silver price volatility and dollar strength impacting the underlying assets. Investors should monitor silver market trends and the ETN's covered call strategy performance for directional cues.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033
SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Read more on SLVO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
